ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,883.14
1.58%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Coherus BioSciences Inc (CHRS)

  7. Coherus BioSciences Inc (CHRS) Noticias

CHRS Coherus BioSciences Inc

2.25
0.08 (3.69%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Coherus BioSciences Inc CHRS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.08 3.69% 2.25 23:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.20 2.19 2.3219 2.27 2.17
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202415:30GLOBECoherus to Report First Quarter 2024 Financial Results on..
24/4/202409:02GLOBECoherus Announces Presentation at the 2024 American Society..
08/4/202407:30GLOBECoherus Presents Preclinical Data for CHS-1000, a Novel..
13/3/202415:01GLOBECoherus BioSciences Reports Fourth Quarter, Full Year 2023..
05/3/202415:01GLOBECoherus to Report Fourth Quarter and Full Year 2023..
04/3/202405:22EDGAR2Form 8-K - Current report
04/3/202400:00GLOBECoherus Completes Divestiture of Ophthalmology Franchise
23/2/202416:33GLOBECoherus BioSciences Announces New Employment Inducement..
22/2/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202416:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/2/202415:59EDGAR2Form 8-K - Current report
21/2/202407:30GLOBECoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and..
05/2/202407:09EDGAR2Form 8-K - Current report
05/2/202407:00GLOBECoherus Amends Term Loan Agreement with Pharmakon Advisors,..
23/1/202419:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202407:01EDGAR2Form 8-K - Current report
22/1/202400:59DJNSandoz to Acquire Cimerli Business from Coherus for $170..
22/1/202400:15GLOBECoherus Announces Agreement to Divest Ophthalmology..
18/1/202415:05GLOBECoherus Presents Positive Phase 2 Clinical Data on..
09/1/202420:41EDGAR2Form 8-K - Current report
09/1/202420:39EDGAR2Form 8-K - Current report
09/1/202418:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202417:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202407:00PRNUSINOVIO and Coherus Announce Clinical Collaboration to..
03/1/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202408:00GLOBECoherus BioSciences Management to Present at the 42nd Annual..
02/1/202407:29GLOBECoherus Announces U.S. Launch of LOQTORZI™
27/12/202308:15APSAnother Biotech Massively Outperforming Broader Equities
27/12/202305:08IHMARKETNEWSWall Street Highlights: Apple Appeals Watch Ban, Tesla to..
26/12/202315:43DJNCoherus BioSciences Gets FDA OK for Udenyca Injector
26/12/202315:01GLOBECoherus Announces FDA Approval of UDENYCA ONBODY™, a Novel..
22/12/202316:00GLOBECoherus BioSciences Announces New Employment Inducement..
15/12/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:13EDGAR2Form 8-K - Current report
11/12/202307:30GLOBECoherus Announces Updated NCCN Clinical Practice Guidelines..
07/12/202316:55GLOBECoherus BioSciences Announces CFO Transition Plans
07/12/202316:16EDGAR2Form 8-K - Current report
06/12/202303:00GLOBECoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a..
28/11/202310:16GLOBECoherus and Junshi Biosciences Announce Publication of..
27/11/202315:03EDGAR2Form 8-K - Current report
13/11/202305:07EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202315:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:31EDGAR2Form 8-K - Current report
06/11/202315:07GLOBECoherus BioSciences Reports Third Quarter 2023 Financial..
06/11/202305:07EDGAR2Form 8-K/A - Current report: [Amend]
03/11/202307:30GLOBECoherus Presents Data from Next-generation Immuno-oncology..
02/11/202319:00GLOBECoherus BioSciences to Participate at Upcoming November..

Su Consulta Reciente

NASDAQ
CHRS
Coherus BioSciences
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados